Managing breakthrough pain

Current Pain and Headache Reports

Volumn 15, Issue 4, 2011, Pages 244-249

  Mercadante, Sebastiano ^a  

^a LA MADDALENA CANCER CENTER   (Italy)

Author keywords

Breakthrough pain; Cancer pain; Opioids

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; FENTANYL; HYDROMORPHONE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PLACEBO;

ALGORITHM; BREAKTHROUGH CANCER PAIN; CANCER PAIN; CLINICAL ASSESSMENT; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SELF ADMINISTRATION; HUMAN; REVIEW; UNSPECIFIED SIDE EFFECT;

ANALGESICS, OPIOID; HUMANS; NEOPLASMS; PAIN; PAIN, INTRACTABLE;

EID: 80051666397     PISSN: 15313433     EISSN: 15343081     Source Type: Journal    
DOI: 10.1007/s11916-011-0191-5     Document Type: Review

References (30)

1. RK Portenoy NA Hagen 1990 Breakthrough pain: definition, prevalence and characteristics Pain 41 273 81 1697056 10.1016/0304-3959(90)90004-W 1:STN:280:DyaK3czls1aktw%3D%3D (Pubitemid 20187930)
2. RK Portenoy D Payne P Jacobson 1999 Breakthrough pain: characteristics and impact in patients with cancer pain Pain 81 129 34 10353500 10.1016/S0304-3959(99)00006-8 1:STN:280:DyaK1M3nvF2nsg%3D%3D (Pubitemid 29199908)
3. G Zeppetella CA O'Doherty S Collins 2000 Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice J Pain Symptom Manage 20 87 92 10989246 10.1016/S0885-3924(00)00161-5 1:STN:280: DC%2BD3cvktlKnsA%3D%3D
4. SS Hwang VT Chang B Kasimis 2003 Cancer breakthrough pain characteristics and responses to treatment at a VA medical center Pain 101 55 64 12507700 10.1016/S0304-3959(02)00293-2 (Pubitemid 36044654)
5. A Caraceni C Martini E Zecca RK Portenoy, et al. 2004 Working Group of an IASP Task Force on Cancer Pain. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey Palliat Med 18 177 83 15198130 10.1191/0269216304pm890oa (Pubitemid 38771657)
6. S Mercadante L Radbruch A Caraceni, et al. 2002 Episodic (breakthrough) pain Cancer 94 832 9 11857319 10.1002/cncr.10249 (Pubitemid 34132314)
7. NA Hagen C Stiles C Nekolaichuk P Biondo LE Carlson K Fisher, et al. 2008 The Alberta Breakthrough pain assessment tool for cancer patients. A validation study using a Delphi process and patient think-alound interview J Pain Symptom Manage 35 136 52 18178370 10.1016/j.jpainsymman.2007.05.011 (Pubitemid 351410457)
8. A Wardley N Davidson P Barrett-Lee A Hong J Mansi D Dodwell, et al. 2005 Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration Br J Cancer 92 1869 76 15870721 10.1038/sj.bjc.6602551 1:CAS:528:DC%2BD2MXkt1Shu70%3D (Pubitemid 40826135)
9. H Smith A Navani SM Fishman 2004 Radiopharmaceuticals for palliation of painful osseous metastases Am J Hosp Palliat Care 21 303 13 15315195 10.1177/104990910402100415 (Pubitemid 39107568)
10. P Rey A Vecino AS Rubiales F Lopez-Lara 2003 Criteria of pain response to radiotherapy in advanced cancer patients J Pain Symptom Manage 25 197 12614952 10.1016/S0885-3924(02)00709-1 (Pubitemid 36287076)
11. C Ripamonti E Fagnoni T Campa V Giardina C Brunelli A Pigni, et al. 2007 Decreases in pain at rest and movement-related pain during zoledronic acid treatment in patients with bone metastases due to breast or prostate cancer: a pilot study Support Care Cancer 15 1177 84 17333295 10.1007/s00520-007-0230-2 (Pubitemid 47459863)
12. S Mercadante P Villari P Ferrera M Dabbene 2001 Pamidronate in incident pain due to bone metastases J Pain Symptom Manage 22 630 1 11503631 10.1016/S0885-3924(01)00322-0 1:STN:280:DC%2BD3MvlvVChtg%3D%3D (Pubitemid 32725802)
13. C Ripamonti E Fagnoni T Campa E Seregni M Maccauro E Bombardieri 2007 Incident pain and analgesic consumption decrease after samarium infusion: a pilot study Support Care Cancer 15 339 42 16967302 10.1007/s00520-006-0131-9 (Pubitemid 46295208)
14. S Mercadante P Villari P Ferrera A Casuccio 2004 Optimization of opioid therapy for preventing incident pain associated with bone metastases J Pain Symptom Manage 28 505 10 15504626 10.1016/j.jpainsymman.2004.02.024 1:CAS:528:DC%2BD2cXhtVOqsbzP (Pubitemid 39422489)
15. GW Hanks F De Conno N Cherny, et al. 2001 Morphine and alternative opioids in cancer pain: the EAPC recommendations Br J Cancer 84 587 93 11237376 10.1054/bjoc.2001.1680 1:CAS:528:DC%2BD3MXisVerur8%3D (Pubitemid 32238990)
16. G Zeppetella 2008 Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief J Pain Symptom Manage 35 563 7 18258412 10.1016/j.jpainsymman.2007.06.012
17. D Bennett AW Burton S Fishman, et al. 2005 Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2-Management Pharm Ther 30 354 61 (Pubitemid 40885216)
18. J Christie M Simmonds R Patt, et al. 1998 Dose-titration multicenter study of transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain J Clin Oncol 16 3238 45 9779697 1:CAS:528:DyaK1cXmvFGrtLo%3D (Pubitemid 28481617)
19. P Coluzzi L Schwartzberg J Conroy, et al. 2001 Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulphate immediate release (MSIR) Pain 91 123 30 11240084 10.1016/S0304-3959(00)00427-9 1:CAS:528:DC%2BD3MXhs1eiu70%3D (Pubitemid 32274181)
20. J Farrar J Cleary R Rauck, et al. 1998 Oral transmucosal fentanyl citrate: a randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients J Natl Cancer Inst 90 611 6 9554444 10.1093/jnci/90.8.611 1:CAS:528:DyaK1cXivFGisbg%3D (Pubitemid 28204805)
21. RK Portenoy R Payne P Coluzzi, et al. 1999 Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study Pain 79 303 12 10068176 10.1016/S0304-3959(98) 00179-1 1:CAS:528:DyaK1cXotVKhsb4%3D (Pubitemid 29076765)
22. RK Portenoy D Taylor J Messina L Tremmel 2006 A randomized, pladebo-controlled study of fentanyl buccal tablets for breakthrough pain in opioid-treated patients with cancer Clin J Pain 22 805 11 17057563 10.1097/01.ajp.0000210932.27945.4a (Pubitemid 44627444)
23. NE Slatkin F Xie J Messina TJ Segal 2007 Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain J Support Oncol 5 327 34 17708123 1:CAS:528:DC%2BD2sXpsVGju7o%3D (Pubitemid 350055013)
24. HG Kress A Oronska Z Kaczmarek, et al. 2009 Efficacy and tolerability of intranasal fentanyl spray 50 to 200 μg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10 month, open-label extension treatment period Clin Ther 31 1177 91 19695386 10.1016/j.clinthera.2009.05.022 1:CAS:528:DC%2BD1MXhtVCht7rF
25. RK Portenoy A Burton N Gabrail D Taylor 2010 A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain Pain 151 617 24 20800358 10.1016/j.pain.2010.07.028 1:CAS:528:DC%2BC3cXhtlKmsrzF
26. S Mercadante L Radbruck A Davies P Poulain T Sitte P Perkins, et al. 2009 A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial Curr Med Res Opin 25 2805 15 19792837 1:CAS:528:DC%2BD1MXht1Kqu77I This was the first controlled study reporting the efficacy of INFS in comparison with OTFC
27. B Lennernäs I Frank-Lissbrant H Lennernäs KM Kälkner R Derrick J Howell 2010 Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain; results from a randomized phase II study Palliat Med 24 286 93 20015921 10.1177/0269216309356138
28. RL Rauck M Tark E Reyes TG Hayes AJ Bartkowiak D Hassman, et al. 2009 Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain Curr Med Res Opin 25 2877 85 19814586 10.1185/03007990903368310 1:CAS:528:DC%2BD1MXhsVCrsLrJ
29. A Davies J Vriens A Kennett McTeggart 2008 An observational study of oncology patients' utilization of breakthrough pain medication J Pain Symptom Manage 35 406 11 18222631 10.1016/j.jpainsymman.2007.05.010
30. S Mercadante 2009 Breakthrough pain: on the road again Eur J Pain 13 329 30 19213583 10.1016/j.ejpain.2008.11.021